TEPOTINIB FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER HARBORING METEX14 SKIPPING ALTERATIONS: A US COST-EFFECTIVENESS ANALYSIS

被引：0
|
作者：
Yang, M. [1 ]
Sachdev, R. [2 ]
Stargardter, M. [2 ]
Tosh, J. [3 ]
Vioix, H. [4 ]
机构：
[1] EMD Serono, Rockland, MA USA
[2] Evidera, Bethesda, MD USA
[3] Evidera, London, England
[4] Merck KGaA, Darmstadt, Germany
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE160
引用
收藏
页码：S365 / S365
页数：1
相关论文
共 50 条
  • [31] Combination tumor-treating fields treatment for patients with metastatic non-small cell lung cancer: A cost-effectiveness analysis
    Liu, Kun
    Zhu, Youwen
    Zhu, Hong
    Zeng, Manting
    CANCER MEDICINE, 2024, 13 (05):
  • [32] Clinical and genomic analysis of non-small cell lung cancer (NSCLC) patients with MET exon14 skipping (METex14) mutations and responses to anti-MET therapy.
    McKenzie, Andrew
    Fisher, Arielle
    Correll, Mick
    Jones, Carissa
    Correia, Jessica
    Thurber, James
    Misch, Amanda
    Heritage, Jessica
    Sturgill, Emma
    Jones, Suzanne Fields
    Johnson, Melissa Lynne
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
    Brazel, Danielle
    Zhang, Shannon
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2022, 13 : 33 - 45
  • [34] COST-EFFECTIVENESS IN THE SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE US
    Graham, C.
    Knox, H.
    Hess, L. M.
    Jen, M.
    Carter, Cuyun G.
    Chandrawansa, K.
    Boye, M.
    VALUE IN HEALTH, 2015, 18 (07) : A457 - A458
  • [35] Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance
    Chen, Shengnan
    Hu, Tao
    Zhao, Jikai
    Zhu, Qian
    Wang, Jin
    Huang, Zhan
    Xiang, Chan
    Zhao, Ruiying
    Zhu, Changbin
    Lu, Shun
    Han, Yuchen
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [36] Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients
    Zheng, Hanrui
    Zeng, Ya
    Wen, Feng
    Hu, Ming
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [37] Tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping mutations: Phase II trial.
    Felip, Enriqueta
    Horn, Leora
    Patel, Jyoti D.
    Sakai, Hiroshi
    Scheele, Juergen
    Bruns, Rolf
    Paik, Paul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study
    Ferreira, Marion
    Swalduz, Aurelie
    Greillier, Laurent
    du Rusquec, Pauline
    Curcio, Hubert
    Raimbourg, Judith
    Toffart, Anne-Claire
    Gounant, Valerie
    Couraudi, Sebastien
    De Chabot, Gonzague
    Friard, Sylvie
    Hureaux, Jose
    Jeannin, Gaelle
    Odier, Luc
    Ricordel, Charles
    Wislez, Marie
    Descarpentries, Clotilde
    Herbreteau, Guillaume
    Missy, Pascale
    Morin, Franck
    Westeel, Virginie
    Cortot, Alexis B.
    LUNG CANCER, 2024, 196
  • [39] Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal or bone metastases in the phase II VISION trial
    Gasking, Stephanie
    Reinmuth, Niels
    Mazieres, Julien
    Popat, Sanjay
    Paz-Ares, Luis
    Hook, Emma
    Hatswell, Anthony
    Vlassak, Soetkin
    Johne, Andreas
    Vioix, Helene
    Paik, Paul
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 132 - 133
  • [40] COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB IN METASTATIC ALK plus NON-SMALL CELL LUNG CANCER (NSCLC)
    Montero, Alberto J.
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1211 - S1212
12345